Kyoto University has obtained a research and development patent in the U.S. that covers new drugs incorporating variant cells and tissues made from induced pluripotent stem cells, according to its Center for iPS Cell Research and Application.
The patent given to the university, which also patented a method for creating iPS cells, will cover the use and sale of both cells and tissue produced from such cells, which are artificially derived from an adult cell, the officials said Friday.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.